| id,files,title,caption |
| F1_Study_Workflow,"['F1_Study_Workflow.png', 'F1_Study_Workflow.pdf']",End-to-end study workflow,All stages derive from raw upstream releases in the same fresh run. The therapeutic analysis is C1-selected but not an independent biological cohort. |
| F2_Primary_C1_Results,"['F2_Primary_C1_Results.png', 'F2_Primary_C1_Results.pdf']",Top primary co-mutation dependency associations,"Frozen pan-cancer C1, q_global_BY<=0.05. Effects are conditional associations, not causal synthetic lethality." |
| F3_Discovery_Drug_Evidence_Funnel,"['F3_Discovery_Drug_Evidence_Funnel.png', 'F3_Discovery_Drug_Evidence_Funnel.pdf']",Statistical discovery and therapeutic corroboration,Distinct statistical families and units: C1 gene-association rows versus PRISM drug comparisons; counts must not be interpreted as independent validations. |
| F4_C2_Effect_Stability,"['F4_C2_Effect_Stability.png', 'F4_C2_Effect_Stability.pdf']",Internal C2 refit stability,Model and lineage deletion sensitivity; no external replication asserted. |
| F5_Reactome_Enrichment,"['F5_Reactome_Enrichment.png', 'F5_Reactome_Enrichment.pdf']",Enriched Reactome terms in discovery contexts,"Source: pinned Reactome v98; labels are pathway associations, not molecular mediation." |
| F6_PRISM_Conditional_Sensitivity,"['F6_PRISM_Conditional_Sensitivity.png', 'F6_PRISM_Conditional_Sensitivity.pdf']",PRISM conditional pharmacological sensitivity associations,"A+B versus A-only (BH q<=0.05, expected direction); negative AUC contrast implies greater drug sensitivity. Other significant discordant tests remain in T7." |
| F7_PRISM_Four_Group_AxB_And_Bonly,"['F7_PRISM_Four_Group_AxB_And_Bonly.png', 'F7_PRISM_Four_Group_AxB_And_Bonly.pdf']",Four-group auxiliary testing and null evidence,Strict and pooled A×B and B-only contrasts are secondary tests. A non-significant interaction is not equivalence and does not negate the primary conditional comparison. |
| F8_TCGA_Selected_CoMutation_Prevalence,"['F8_TCGA_Selected_CoMutation_Prevalence.png', 'F8_TCGA_Selected_CoMutation_Prevalence.pdf']",Selected TCGA co-mutation prevalence,"Descriptive prevalence in selected TCGA study cohorts, different mutation definition from DepMap and no patient efficacy inference." |
|
|
